Figure 2
Status of RAD50, NPM1 and XRCC5 in DSB-repair pathway and modulation of their expression on E 2 and cisplatin treatment. A. Schematic diagram showing designations of RAD50, NPM1 and XRCC5 in HR and NHEJ pathways of DSB-repair. B. Representative immunoblot showing elevated expression of c-Myc on 10nM E2 treatment (upper panel); fold-change expression of c-Myc, NPM1 and RAD50 mRNA and protein (lower panel). C. Representative immunoblots of H2AX-γ, NPM1, RAD50 and XRCC5 on 4 μM Cisplatin treatment; numbers indicate mean fold-change values. D. Immunofluorescence staining indicating NPM1, RAD50 and XRCC5 expression on 4 μM Cisplatin treatment in comparison to untreated control A4-T cells; Scale bar 25 μm. E. Immunofluorescence staining showing translocation of NPM1 from nucleolus to nucleoplasm within 24 h upon 4 μM cisplatin treatment in A4-T cells in comparison to untreated cells. Scale bar 8 μm. Data shown as mean ± SE of triplicate experiments. *p <0.05,**p <0.01.